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Dear Editor, 22 
In response to the recent “call for nitrous oxide in pediatric oncology clinics”[1], we 23 
urge extreme caution. Although this relatively small study did not record significant 24 
acute toxicity, we draw reader’s attention to a serious potential safety concern 25 
regarding use of nitrous oxide in combination with methotrexate, the most commonly 26 
administered intrathecal drug in paediatric oncology. Two recent case reports describe 27 
severe neurotoxicity following the use of nitrous oxide anaesthesia in paediatric 28 
leukaemia patients receiving intrathecal methotrexate[2,3].  Although these do not 29 
prove a causal relationship, there is a body of experimental and clinical data that 30 
support the theory that nitrous oxide may increase the toxicity of anti-folate 31 
medications such as methotrexate[4]. Indeed, the British National Formulary states 32 
“nitrous oxide increases antifolate effect of methotrexate – avoid concomitant use”[5].   33 
Methotrexate related neurotoxicity is common, with 4-12% of children experiencing 34 
neurological adverse events during therapy[2]. Importantly, adverse events often have 35 
delayed presentation several days or longer after methotrexate administration. In 36 
addition, up to 20% of children have subclinical leukoencephalopathy on MRI 37 
scanning, and both clinical neurotoxicity and subclinical leukoencephalopathy are 38 
associated with adverse long-term neurocognitive outcomes[6]. It is crucial that all 39 
possible measures are taken to reduce this significant side effect of methotrexate, and 40 
the absence of immediate side effects from nitrous oxide anaesthesia does not 41 
necessarily equate to an absence of long-term impact on neurocognition.  42 
Preclinical studies in rats have shown that intraperitoneal methotrexate combined with 43 
pre-treatment nitrous oxide administration, decreased the 50% lethal dose of 44 
methotrexate by 6-fold from 60mg/kg to 10mg/kg, with the authors recommending 45 
against use of nitrous oxide before or during methotrexate administration in humans 46 
based on their findings[7].  In addition, a clinical study in patients with breast cancer 47 
showed that severe unpredictable toxic effects from methotrexate were probably due 48 
to an interaction with nitrous oxide[8].  49 
Mechanistically, methotrexate inhibits the enzyme dihydrofolate reductase, leading to 50 
disruption of one-carbon metabolism important for nucleotide synthesis and amino 51 
acid metabolism. One consequence of reduced bioavailability of folates in the one-52 
carbon cycle is a reduction in methionine synthase activity leading to increased 53 
homocysteine levels and reduced methionine levels. Downstream metabolites of 54 
homocysteine act at the NMDA receptor to cause neurotoxicity in preclinical models[9] 55 
and human data confirm the link between homocysteine, NMDA activation and clinical 56 
methotrexate-associated neurotoxicity[10]. Nitrous oxide also inhibits methionine 57 
synthase via irreversibly inactivating its essential cofactor – vitamin B12[7]. The same 58 
pathway is implicated in the pathogenesis of the serious neurological syndrome 59 
subacute combined degeneration of the cord, seen following nitrous oxide use in 60 
patients with untreated vitamin B12 deficiency. As a second cautionary note, patients 61 
with haematological malignancies may be at increased risk for subclinical vitamin B12 62 
deficiency due to chronic proton pump inhibitor use, enteropathy and/or 63 
malnutrition[2].  64 
Therefore, given the potential for enhanced neurotoxicity, we urge all paediatric 65 
oncology units to take a precautionary principle and avoid the use of nitrous oxide in 66 
patients undergoing lumbar puncture for administration of intrathecal methotrexate.  67 
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